TACERE THERAPEUTICS, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2006-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.tacerebio.com
Clinical Trials
2
Active:0
Completed:1
Trial Phases
1 Phases
Phase 1:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (100.0%)Long-Term Follow-Up Safety Monitoring of Patients Dosed in the First-in-Man Phase I/II Study of TT-034.
Terminated
- Conditions
- Hepatitis C
- First Posted Date
- 2014-12-12
- Last Posted Date
- 2018-09-26
- Lead Sponsor
- Tacere Therapeutics, Inc.
- Target Recruit Count
- 9
- Registration Number
- NCT02315638
- Locations
- 🇺🇸
Duke Clinical Research Institute, Durham, North Carolina, United States
Safety and Efficacy Study of Single Doses of TT-034 in Patients With Chronic Hepatitis C
- First Posted Date
- 2013-07-15
- Last Posted Date
- 2016-11-30
- Lead Sponsor
- Tacere Therapeutics, Inc.
- Target Recruit Count
- 9
- Registration Number
- NCT01899092
- Locations
- 🇺🇸
UCSD Antiviral Research Center, San Diego, California, United States
🇺🇸Duke Clinical Research Institute, Durham, North Carolina, United States
🇺🇸The Liver Institute at Methodist Dallas, Dallas, Texas, United States
News
No news found